[go: up one dir, main page]

CY1109135T1 - Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο - Google Patents

Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο

Info

Publication number
CY1109135T1
CY1109135T1 CY20091100675T CY091100675T CY1109135T1 CY 1109135 T1 CY1109135 T1 CY 1109135T1 CY 20091100675 T CY20091100675 T CY 20091100675T CY 091100675 T CY091100675 T CY 091100675T CY 1109135 T1 CY1109135 T1 CY 1109135T1
Authority
CY
Cyprus
Prior art keywords
water
solvent
long chain
pharmaceutical solution
oil fat
Prior art date
Application number
CY20091100675T
Other languages
English (en)
Inventor
Laman A Alani
Soumojeet Ghosh
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109135(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1109135T1 publication Critical patent/CY1109135T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Προσφέρονται (προμηθεύονται) βελτιωμέναι φαρμακευτικαί συνθέσεις αι οποίαι περιλαμβάνουν μίαν ή περισσοτέρας ανασταλτικάς ενώσεις πρωτεάσης HIV, έχουσαι βελτιωμένας ιδιότητας διαλύσεως εις μίγμα λιπαρού οξέος, αιθανόλης και ύδατος.
CY20091100675T 1999-06-04 2009-06-29 Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο CY1109135T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32582699A 1999-06-04 1999-06-04
EP06114684A EP1733725B2 (en) 1999-06-04 2000-05-25 Pharmaceutical solution comprising ritonavir, a solvent (long chain fatty acid) and water

Publications (1)

Publication Number Publication Date
CY1109135T1 true CY1109135T1 (el) 2014-07-02

Family

ID=23269615

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061101354T CY1105237T1 (el) 1999-06-04 2006-09-21 Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
CY20091100675T CY1109135T1 (el) 1999-06-04 2009-06-29 Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20061101354T CY1105237T1 (el) 1999-06-04 2006-09-21 Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir

Country Status (33)

Country Link
EP (2) EP1733725B2 (el)
JP (1) JP4753511B2 (el)
KR (1) KR100815412B1 (el)
CN (2) CN100418527C (el)
AR (2) AR032586A1 (el)
AT (2) ATE429224T1 (el)
AU (1) AU778198B2 (el)
BG (1) BG65445B1 (el)
BR (1) BR0007294A (el)
CA (1) CA2371109C (el)
CL (1) CL2008003491A1 (el)
CO (1) CO5160323A1 (el)
CY (2) CY1105237T1 (el)
CZ (1) CZ301308B6 (el)
DE (2) DE60042092D1 (el)
DK (2) DK1733725T4 (el)
ES (2) ES2324549T5 (el)
HK (1) HK1045804A1 (el)
HU (1) HU229501B1 (el)
IL (3) IL146025A0 (el)
MX (1) MXPA01012478A (el)
MY (1) MY127908A (el)
NO (1) NO328968B1 (el)
NZ (1) NZ515016A (el)
PL (1) PL197671B1 (el)
PT (2) PT1183026E (el)
SA (1) SA00210237B1 (el)
SI (2) SI1183026T1 (el)
SK (2) SK287185B6 (el)
TR (1) TR200103488T2 (el)
TW (1) TWI244390B (el)
WO (1) WO2000074677A2 (el)
ZA (1) ZA200108641B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DE60042092D1 (de) * 1999-06-04 2009-06-04 Abbott Lab Arzneizubereitungen enthaltend mindestens einen HIV Preoteaseinhibitor
JP5767429B2 (ja) 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
CZ304118B6 (cs) * 2000-01-19 2013-11-06 Abbott Laboratories Farmaceutická kompozice
CA2448438A1 (en) * 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
SG170795A1 (en) * 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2015258296B2 (en) * 2006-07-07 2017-08-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2013204805C1 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2015234299B2 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
NO347119B1 (no) * 2006-07-07 2023-05-15 Gilead Sciences Inc Modulatorer av farmakokinetikkegenskaper til terapeutika
WO2008010921A2 (en) * 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
KR101577698B1 (ko) 2007-02-23 2015-12-15 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
RS55280B1 (sr) 2007-02-23 2017-03-31 Gilead Sciences Modulatori farmakokinetičkih svojstava lekova
AU2013204815B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN101796040A (zh) * 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
JP5629585B2 (ja) 2008-01-04 2014-11-19 ギリアード サイエンシーズ， インコーポレイテッド シトクロムｐ４５０のインヒビター
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL110752A (en) † 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
DE4431489A1 (de) * 1994-09-03 1996-03-07 Heidelberger Baustofftech Gmbh Schnellhärtende aminosilanvernetzende Silikonmassen
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
EP1295874A3 (en) * 1995-12-13 2003-04-02 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
DE60042092D1 (de) * 1999-06-04 2009-06-04 Abbott Lab Arzneizubereitungen enthaltend mindestens einen HIV Preoteaseinhibitor

Also Published As

Publication number Publication date
BG106239A (en) 2002-08-30
NZ515016A (en) 2004-02-27
JP2003501386A (ja) 2003-01-14
CN101361723A (zh) 2009-02-11
WO2000074677A3 (en) 2001-02-22
AU778198B2 (en) 2004-11-25
NO20015670D0 (no) 2001-11-20
EP1183026B1 (en) 2006-07-05
HU229501B1 (hu) 2014-01-28
WO2000074677A2 (en) 2000-12-14
DK1733725T3 (da) 2009-08-03
BG65445B1 (bg) 2008-08-29
SI1733725T1 (sl) 2009-08-31
PL351943A1 (en) 2003-07-14
AR064309A2 (es) 2009-03-25
HUP0201591A3 (en) 2002-10-28
EP1183026A2 (en) 2002-03-06
ATE332132T1 (de) 2006-07-15
CL2008003491A1 (es) 2009-03-06
PL197671B1 (pl) 2008-04-30
DE60042092D1 (de) 2009-06-04
CN101361723B (zh) 2013-11-06
ATE429224T1 (de) 2009-05-15
CN1353607A (zh) 2002-06-12
ES2324549T3 (es) 2009-08-10
AU5287700A (en) 2000-12-28
NO20015670L (no) 2001-11-20
EP1733725A1 (en) 2006-12-20
DE60029219D1 (de) 2006-08-17
CY1105237T1 (el) 2010-03-03
ES2265946T3 (es) 2007-03-01
CO5160323A1 (es) 2002-05-30
JP4753511B2 (ja) 2011-08-24
PT1183026E (pt) 2006-11-30
DK1733725T4 (da) 2012-09-17
HUP0201591A2 (en) 2002-09-28
DE60029219T2 (de) 2007-06-28
TR200103488T2 (tr) 2002-04-22
KR100815412B1 (ko) 2008-03-20
KR20020011994A (ko) 2002-02-09
IL146025A (en) 2012-04-30
EP1733725B1 (en) 2009-04-22
IL216686A (en) 2014-01-30
NO328968B1 (no) 2010-06-28
SK286305B6 (en) 2008-07-07
AR032586A1 (es) 2003-11-19
CZ301308B6 (cs) 2010-01-06
EP1733725B2 (en) 2012-08-08
CN100418527C (zh) 2008-09-17
TWI244390B (en) 2005-12-01
SI1733725T2 (sl) 2012-10-30
CA2371109C (en) 2011-04-26
IL146025A0 (en) 2002-07-25
PT1733725E (pt) 2009-06-30
SK17202001A3 (sk) 2002-03-05
BR0007294A (pt) 2002-08-27
DK1183026T3 (da) 2006-11-06
IL216686A0 (en) 2012-01-31
ES2324549T5 (es) 2012-10-31
CZ20014293A3 (cs) 2002-03-13
MXPA01012478A (es) 2003-10-14
MY127908A (en) 2006-12-29
CA2371109A1 (en) 2000-12-14
SK287185B6 (sk) 2010-02-08
HK1045804A1 (en) 2002-12-13
ZA200108641B (en) 2003-01-20
SA00210237B1 (ar) 2006-11-07
SI1183026T1 (sl) 2006-10-31

Similar Documents

Publication Publication Date Title
CY1109135T1 (el) Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο
CY1120408T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες
CR7171A (es) Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ECSP055529A (es) Composicion herbicida
BR9807824A (pt) Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
GT200200125A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
ATE274330T1 (de) Gleitschutz fur einen gehäusekopf medizinischer instrumente
DE60104206D1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
PA8548001A1 (es) Derivados aromaticos de acidos dicarboxilicos
BR9714310A (pt) Composição farmacêutica
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
BR0112835A (pt) Derivados de moléculas lipofìlicas de cadeia ramificada e seus usos
DE60115402D1 (de) Neues selbstemulgierendes arzneistoffverabreichungssystem
UY27133A1 (es) 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides
ITMI20000554A0 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
BR0106423B1 (pt) p-aminofenàis e agentes de tingimento que contÊm esses compostos.
AR012019A1 (es) Compuesto de criptoficina y su uso para preparar un medicamento